Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements

Authors: Julia Wulfkuhle, Denise M. Wolf, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Hope S. Rugo, Lajos Pusztai, Lamorna Brown-Swigart, Gillian L. Hirst, Rosa I. Gallagher, Amy L. Delson, Alexander D. Borowsky, Laura J. Esserman, Paula R. Pohlmann, Emanuel F. Petricoin

Published: 2024-02-01

DOI: 10.1158/1538-7445.advbc23-a026

Source: Full article